Atai Beckley (ATAI) has quietly become one of the more talked about mental health biotech names this year, with the stock swinging sharply even as its late stage psychedelic pipeline moves through key ...

atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living with mental health conditions Continued operational ...

- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study in treatment-resistant ...

NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop ...

VLS-01, a proprietary oral transmucosal film (OTF) formulation of DMT, was well-tolerated with a favorable safety profile Pharmacokinetic and pharmacodynamic data confirmed systemic delivery of DMT ...

Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the best multibagger penny stocks to buy right now. ATAI Life Sciences holds a Strong Buy consensus from 8 analysts, with a 12‑month average target of ...

Investors might want to bet on atai Life Sciences N.V. (ATAI), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

The biotech earned an important fast-track review designation from a major regulator. This should speed the development (and potentially, commercialization) of one of its investigational treatments.

Atai Beckley (ATAI) has been on a wild ride this year, with the stock up over 140% year to date even after a sharp pullback over the past month. See our latest analysis for Atai Beckley. The latest 1 ...

NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health ...